Vaccine Adjuvants Market to Reach USD 1,375.9 Million by 2030 Amid Rising Infectious Diseases

In 2024, the worldwide vaccine adjuvants industry was valued at USD 930.7 million, which is projected to attain USD 1,375.9 million by the end of 2030, advancing at a CAGR of 6.7% over the projection period. 

This development of the market can be credited to the increasing occurrence of communicable illnesses and the mounting usage of vaccine adjuvants, as a result. There has been a tremendous surge in the load of infectious diseases, like TB, HIV, and malaria, in recent years. This has led to a surge in the utilization of therapeutic and prophylactic vaccines, which, ultimately, has fuelled the demand for adjuvants.

Government officials and pharmaceutical and biotechnology firms have recognized the importance of infectious disease research following the emergence of the novel coronavirus. For example, the U.S. Department of Health and Human Services, through the Health Resources and Services Administration (HRSA), introduced a new initiative in November 2022. 

This USD 350 million initiative aims to boost COVID-19 vaccination rates in communities served by HRSA-supported health centers, focusing particularly on marginalized populations. Additionally, the U.S. has committed USD 122 million to three prominent medical research institutions in India to enhance early detection of disease threats and ensure swift and effective responses to prevent future epidemics.

• Particulate Category: Particulates held the largest market share of 35% in 2023, driven by products like alum, virosomes, and cytokines known for enhancing vaccine efficacy.

• Emulsions also showed significant growth due to increased adoption in adjuvanted vaccines against SARS-CoV-2.

• Pathogen Category Growth: The pathogen category is expected to grow the fastest at a CAGR of 7.5%, supported by advancements like Monophosphoryl lipid A used in vaccines such as Cervarix.

• Infectious diseases led the disease type segment with a 45% share in 2023, driven by rising incidences of hepatitis, influenza, and malaria.

• The cancer category is set to expand rapidly due to active research on targeted therapies, including the use of adjuvanted vaccines like Cervarix.

• Intramuscular administration captured the largest market share (30%) in 2023, favored for its immunological specificity and effectiveness in delivering vaccines such as HPV and influenza.

• Intradermal and Intranasal Categories: Intradermal administration is projected to grow significantly due to prolonged action and absorption benefits, while intranasal vaccines are gaining popularity for their comfort and efficacy post-COVID-19.

• North America dominated the market with a 45% share in 2023, driven by top players, advanced healthcare infrastructure, technological innovations, and supportive healthcare policies.

• Europe is expected to hold a substantial share, driven by an aging population, increasing chronic diseases, and robust introduction of new products like the VLA2001 COVID-19 vaccine.